Oramed Pharmaceuticals Inc SEC Filings

Oramed Pharmaceuticals Inc. adopted a shareholder rights plan by declaring a dividend of one common stock purchase right for each outstanding share of common stock. The dividend will be paid on November 27, 2025 to holders of record on that date. Each right initially allows the holder to buy one share of common stock from the company at $10.00 per share, subject to adjustment. The rights become separable and trade independently only if a person or group acquires, or launches an offer to acquire, generally 15% or more of Oramed’s common stock. If that happens, other right holders can acquire common stock (or, in some cases, stock of an acquiring company) with a market value equal to two times the exercise price, while the acquiring person’s rights become void. The rights expire three years after the agreement date unless earlier redeemed by the board at $0.012 per right or exchanged for common stock.

Oramed Pharmaceuticals (ORMP) reported a swing to profitability driven by investment revaluations. For the nine months ended September 30, 2025, net income attributable to stockholders was $54,041 thousand, including third‑quarter net income of $48,395 thousand. Financial income, net, reached $74,278 thousand, reflecting fair value gains primarily on Alpha Tau and Scilex exposures.

Total assets were $220,493 thousand with stockholders’ equity of $203,282 thousand. Cash and cash equivalents were $52,179 thousand. The company recognized $2,000 thousand of revenue tied to the HTIT License Agreement, while cost of revenue of $1,987 thousand related to IIA obligations.

Oramed expanded its investment portfolio: its Alpha Tau stake measured at fair value was $64,803 thousand, and it holds a 50% interest in RoyaltyVest. With Scilex, Oramed received $13,000 thousand from the repurchase of 3,130,000 Subsequent Penny Warrants and retains an option for $14,000 thousand on 3,370,000 additional warrants on or before December 31, 2025. The company also continued a buyback program, repurchasing $732 thousand of shares year‑to‑date.

Oramed Pharmaceuticals (ORMP) repurchased and retired shares and ended a planned joint venture. On October 20, 2025, the company bought back 1,155,367 shares of its common stock from Hefei Tianhui Biotech Co., Ltd. at $2.23 per share for an aggregate $2,576,468.41. The transaction closed the same day, and the shares were cancelled and retired, reducing the share count.

On October 23, 2025, Oramed terminated its Joint Venture Agreement and a related Supplemental Agreement with HTIT after HTIT was unable to satisfy closing conditions. The company also furnished a shareholder letter with preliminary, unaudited financial information as of September 30, 2025, accompanied by cautionary language noting that results are subject to adjustment and may materially vary.

Oramed Pharmaceuticals insider amendment outlines updated beneficial ownership and equity awards for reporting person Nadav Kidron. Mr. Kidron reports beneficial ownership of 3,116,729 shares, representing approximately 7.6% of the company’s outstanding common stock based on 41,003,600 shares outstanding. The filing discloses 762,750 stock options exercisable or issuable within 60 days, 63,541 RSUs vesting within 60 days, 73,500 vested-but-not-issued RSUs and 218,603 shares held by a former director, Xiaopeng Li. The amendment details grants since the original Schedule 13D, including RSU and PSU awards with specified vesting events and that certain PSUs vested on February 11, 2025.

Oramed Pharmaceuticals, Inc. reports condensed consolidated interim results and disclosures for the quarter ended June 30, 2025. The company operates in a single reportable segment focused on research and development of orally delivered pharmaceuticals and vaccines. The filing details multiple strategic investments and financing arrangements, including a $36,900 investment in Alpha Tau Medical (yielding an unrealized gain of $7,138 recognized in the six months ended June 30, 2025), equity method accounting for a 50% interest in RoyaltyVest, and various loans and real estate investments presented at fair value.

The company continues to hold structured receivables and convertible notes related to Scilex, including Tranche A and Tranche B Notes, and warrants (including 6,500,000 Subsequent Penny Warrants) with monetization restrictions; as of June 30, 2025 Scilex had repaid $69,200 of the Tranche A Note. The company entered an Option Agreement (July 22, 2025) under which Scilex may repurchase Subsequent Penny Warrants for a total of $27,000, and the agreement could extend the Tranche A Note maturity if completed. The company discloses deferred revenue recognition related to an HTIT license arrangement and describes cash flows, fair value measurements, share-based compensation grants (PSUs/RSUs), and a limited stock repurchase program under which 163,869 shares were repurchased for $371.

Oramed Pharmaceuticals (ORMP) filed an 8-K disclosing an Option Agreement signed 22-Jul-25 with Scilex Holding. The accord gives Scilex the right to repurchase Oramed’s remaining 6.5 M “Penny Warrants” (exercise price $0.01/sh) in two tranches for a total cash consideration of $27 M. To secure the option, Scilex will pay Oramed $1.5 M in two equal installments due 8-Aug-25 and 16-Dec-25.

• Tranche 1: up to 3.13 M warrants for $13 M if exercised by 30-Sep-25.
• Tranche 2: up to 3.37 M warrants for $14 M if exercised by 31-Dec-25.

If Scilex completes the repurchase and makes all payments, the maturity of the $101.9 M Tranche A senior secured note held by Oramed will be extended to 31-Mar-26 and its make-whole prepayment penalty waived.

Until the earlier of option expiry or termination, Oramed has agreed not to exercise the warrants. Oramed can terminate the agreement if Scilex misses any payment or fails to exercise by the set dates. Post-termination, Scilex will seek shareholder approval to permit stock issuance above a 19.9 % cap should Oramed later exercise retained warrants.

The filing also clarifies prior disclosure: despite Scilex’s 1-for-35 reverse split, the Penny Warrant exercise price remains $0.01 and the quantity remains 6.5 M shares; no impact to previously reported Q1-25 financials.